DOP2012000030A - Polipéptidos del factor ix modificados y usos de los mismos - Google Patents
Polipéptidos del factor ix modificados y usos de los mismosInfo
- Publication number
- DOP2012000030A DOP2012000030A DO2012000030A DO2012000030A DOP2012000030A DO P2012000030 A DOP2012000030 A DO P2012000030A DO 2012000030 A DO2012000030 A DO 2012000030A DO 2012000030 A DO2012000030 A DO 2012000030A DO P2012000030 A DOP2012000030 A DO P2012000030A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- polipeptides
- factor
- same
- modified factor
- modified
- Prior art date
Links
- 229960004222 factor ix Drugs 0.000 title abstract 5
- 238000000034 method Methods 0.000 abstract 2
- 208000031220 Hemophilia Diseases 0.000 abstract 1
- 208000009292 Hemophilia A Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23055109P | 2009-07-31 | 2009-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2012000030A true DOP2012000030A (es) | 2012-02-29 |
Family
ID=43529743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2012000030A DOP2012000030A (es) | 2009-07-31 | 2012-01-27 | Polipéptidos del factor ix modificados y usos de los mismos |
Country Status (21)
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2655639T3 (es) | 2006-12-15 | 2018-02-21 | Baxalta GmbH | Conjugado de factor VIIa - ácido (poli)siálico que tiene una semivida in vivo prolongada |
PT3581650T (pt) | 2008-09-15 | 2023-03-08 | Uniqure Biopharma B V | Mutante de polipéptido de fator ix, as suas utilizações e um método para a sua produção |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
SG10201401194VA (en) | 2009-07-27 | 2014-07-30 | Lipoxen Technologies Ltd | Glycopolysialylation of non-blood coagulation proteins |
AU2010281453C1 (en) | 2009-07-27 | 2019-08-15 | Takeda Pharmaceutical Company Limited | Blood coagulation protein conjugates |
SG178051A1 (en) | 2009-07-27 | 2012-03-29 | Lipoxen Technologies Ltd | Glycopolysialylation of non-blood coagulation proteins |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
SG187171A1 (en) * | 2010-07-30 | 2013-02-28 | Baxter Int | Nucleophilic catalysts for oxime linkage |
HUE049352T2 (hu) | 2010-12-22 | 2020-09-28 | Baxalta GmbH | Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására |
PT2794665T (pt) * | 2011-12-19 | 2018-01-24 | Dilafor Ab | Glicosaminoglicanos não anticoagulativos que compreendem unidade repetitiva de dissacáridos e sua utilização médica |
WO2014081831A1 (en) * | 2012-11-20 | 2014-05-30 | The University Of North Carolina At Chapel Hill | Methods and compositions for modified factor ix proteins |
CA2901928C (en) * | 2013-03-13 | 2017-10-10 | Eli Lilly And Company | Modified canine leptin polypeptides |
TW201519900A (zh) * | 2013-04-28 | 2015-06-01 | Bayer Healthcare Llc | 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法 |
GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
TWI741992B (zh) | 2015-08-03 | 2021-10-11 | 美商百歐維拉提夫治療公司 | 因子ix融合蛋白以及其製備及使用方法 |
EP3490586B1 (en) * | 2016-07-27 | 2025-03-26 | The Children's Hospital of Philadelphia | Compositions and methods for modulating factor ix function |
GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
AU2019360270B2 (en) | 2018-10-18 | 2025-08-07 | Intellia Therapeutics, Inc. | Compositions and methods for expressing factor IX. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002086091A2 (en) * | 2001-04-25 | 2002-10-31 | The Regents Of The University Of California | Method to treat hemophilia by hepatic gene transfer of factor viii/ix with vesicle vector |
NZ546733A (en) * | 2003-12-03 | 2009-07-31 | Novo Nordisk As | Glycopegylated factor IX |
US20060040856A1 (en) * | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
TW200804416A (en) * | 2006-06-19 | 2008-01-16 | Nautilus Technology Llc | Modified coagulation factor IX polypeptides and use thereof for treatment |
US7700734B2 (en) * | 2007-01-09 | 2010-04-20 | Shu-Wha Lin | Recombinant human factor IX and use thereof |
-
2010
- 2010-08-02 AU AU2010278721A patent/AU2010278721A1/en not_active Abandoned
- 2010-08-02 IN IN908DEN2012 patent/IN2012DN00908A/en unknown
- 2010-08-02 CN CN2010800431356A patent/CN102573890A/zh active Pending
- 2010-08-02 SG SG2012005757A patent/SG178119A1/en unknown
- 2010-08-02 KR KR1020127005191A patent/KR20120060209A/ko not_active Withdrawn
- 2010-08-02 MX MX2012001346A patent/MX2012001346A/es not_active Application Discontinuation
- 2010-08-02 EP EP10805185.5A patent/EP2461821A4/en not_active Withdrawn
- 2010-08-02 US US13/388,288 patent/US20120164130A1/en not_active Abandoned
- 2010-08-02 JP JP2012523129A patent/JP2013500726A/ja active Pending
- 2010-08-02 BR BR112012002072A patent/BR112012002072A2/pt not_active IP Right Cessation
- 2010-08-02 WO PCT/US2010/044177 patent/WO2011014890A1/en active Application Filing
- 2010-08-02 CA CA2769258A patent/CA2769258A1/en not_active Abandoned
- 2010-08-02 PE PE2012000114A patent/PE20121643A1/es not_active Application Discontinuation
- 2010-08-02 EA EA201290069A patent/EA201290069A1/ru unknown
-
2012
- 2012-01-27 DO DO2012000030A patent/DOP2012000030A/es unknown
- 2012-01-30 CU CU20120018A patent/CU20120018A7/es unknown
- 2012-01-30 ZA ZA2012/00716A patent/ZA201200716B/en unknown
- 2012-01-30 CL CL2012000238A patent/CL2012000238A1/es unknown
- 2012-01-30 EC EC2012011637A patent/ECSP12011637A/es unknown
- 2012-01-30 GT GT201200023A patent/GT201200023A/es unknown
- 2012-01-30 CR CR20120052A patent/CR20120052A/es unknown
-
2013
- 2013-04-19 CU CU2013000058A patent/CU20130058A7/es unknown
- 2013-04-19 CU CU2013000057A patent/CU20130057A7/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2011014890A1 (en) | 2011-02-03 |
GT201200023A (es) | 2014-01-27 |
IN2012DN00908A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-04-03 |
SG178119A1 (en) | 2012-03-29 |
CU20130058A7 (es) | 2013-06-28 |
JP2013500726A (ja) | 2013-01-10 |
BR112012002072A2 (pt) | 2016-11-08 |
EA201290069A1 (ru) | 2012-07-30 |
CR20120052A (es) | 2012-06-04 |
ZA201200716B (en) | 2013-07-31 |
ECSP12011637A (es) | 2012-02-29 |
AU2010278721A1 (en) | 2012-02-16 |
MX2012001346A (es) | 2012-02-17 |
CU20120018A7 (es) | 2012-06-21 |
EP2461821A1 (en) | 2012-06-13 |
PE20121643A1 (es) | 2012-11-25 |
CN102573890A (zh) | 2012-07-11 |
EP2461821A4 (en) | 2013-07-03 |
CL2012000238A1 (es) | 2012-10-05 |
US20120164130A1 (en) | 2012-06-28 |
CA2769258A1 (en) | 2011-02-03 |
CU20130057A7 (es) | 2013-06-28 |
KR20120060209A (ko) | 2012-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2012000030A (es) | Polipéptidos del factor ix modificados y usos de los mismos | |
SV2010003704A (es) | Polipeptidos modificados del factor ix y usos de los mismos | |
CL2020000501A1 (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos. | |
CR20140512A (es) | Dispositivos y metodos para la fabricación de aditivos de componentes de implante | |
UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
HN2010000084A (es) | Derivados de sulfonamida | |
ECSP14017269A (es) | Compuestos para tratar la atrofia muscular espinal | |
CL2015002941A1 (es) | Usos terapéuticos de empaglifozina | |
MX2015011445A (es) | Compuestos y usos de estos para la modulacion de la hemoglobina. | |
CO6501131A2 (es) | Antagonistas de espiro-oxindol de mdm2 | |
NI201000044A (es) | Bromhidrato de bupropión y aplicaciones terapéuticas | |
PE20150631A1 (es) | Formas cristalinas de un modulador del receptor androgenico | |
CR20140476A (es) | Agentes para tratar transtornos que implican la modulación de receptores de rianodina | |
CR20150067A (es) | Pirazoles sustituidos como bloqueadores del canal de calcio tipo n | |
ECSP109923A (es) | Bromhidrato de bupropion y aplicaciones terapéuticas | |
MX2017014245A (es) | Composiciones que comprenden celulas germinales mesenquimales y usos de las mismas. | |
BR112013005855A2 (pt) | heteroarilas fundidas e seus usos | |
UY34773A (es) | Ácidos indanoiloxidihidrobenzofuranilacéticos como moduladores de la actividad de gpr40, composiciones que los contienen y sus usos | |
CR11631A (es) | Paramyxovirus eficaz como antitumoral | |
CR20150070A (es) | Pirrolopirazoles como bloqueadores del canal de calcio tipo n | |
UY33833A (es) | Proteína de fusión Robo1-Fc para su uso en el tratamiento del hepatocarcinoma | |
MX2017012596A (es) | Una composicion farmaceutica y el uso de la misma. | |
BR112014031706A8 (pt) | Composições farmacêuticas orais, e composição farmacêutica oral compreendendo itraconazol | |
MX372807B (es) | Copolimeros de bloque para proteccion del esmalte dental. | |
MX2016005227A (es) | Polipéptidos de acción prolongada y métodos para su producción y administración. |